With over 4.79 million Corbus Pharmaceuticals Holdings Inc. (CRBP) shares trading Tuesday and a closing price of $0.12 on the day, the dollar volume was approximately $0.57 million. The shares have shown a negative half year performance of -59.95% and its price on 11/29/22 gained nearly 1.50%. Currently, there are 125.27M common shares owned by the public and among those 124.68M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 2 analysts who have offered their price forecasts for CRBP have a consensus price objective of $3.00. The analysts have set the share’s price value over the next 12 months at a high of $3.00 and a low of $3.00. The average price target is 96.0% above its recent price level and an upside to the estimated low will see the stock gain 96.0% over that period. But an upside of 96.0% will see the stock hit the forecast high price target while median target price for the stock is $3.00.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
Insiders at the company have transacted a total of 6 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 6 of these insider trades were purchases, accounting for 62,400 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Corbus Pharmaceuticals Holdings Inc. are ETFMG Alternative Harvest ETF, Vanguard Total Stock Market Index, and Vanguard Extended Market Index Fu. ETFMG Alternative Harvest ETF owns 4.85 million shares of the company’s stock, all valued at over $0.63 million. Vanguard Extended Market Index Fu now owns shares totaling to 1.36% of the shares outstanding.
However, the script later moved the day high at 0.1263, up 1.50%. The company’s stock has a 5-day price change of 8.39% and -40.73% over the past three months. CRBP shares are trading -80.27% year to date (YTD), with the 12-month market performance down to -85.73% lower. It has a 12-month low price of $0.10 and touched a high of $0.90 over the same period. CRBP has an average intraday trading volume of 2.53 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -2.27%, -12.73%, and -54.84% respectively.
Institutional ownership of Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) shares accounts for 19.00% of the company’s 125.27M shares outstanding. Mutual fund holders own 8.80%, while other institutional holders and individual stakeholders account for 9.86% and 7.83% respectively.
It has a market capitalization of $14.26M and a beta (3y monthly) value of 1.77. The earnings-per-share (ttm) stands at -$0.33. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.15% over the week and 8.62% over the month.
Analysts forecast that Corbus Pharmaceuticals Holdings Inc. (CRBP) will achieve an EPS of -$0.05 for the current quarter, -$0.05 for the next quarter and -$0.26 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.07 while analysts give the company a high EPS estimate of -$0.04. Comparatively, EPS for the current quarter was -$0.02 a year ago. Earnings per share for the fiscal year are expected to increase by 73.90%, and 9.70% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 2 brokerage firm advisors rate Corbus Pharmaceuticals Holdings Inc. (CRBP) as a “Moderate Buy” at a consensus score of 2.50. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 1 of the 2 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the CRBP, a number of firms have released research notes about the stock. ROTH Capital stated their Neutral rating for the stock in a research note on September 08, 2020, with the firm’s price target at $40-$3. ROTH Capital on their part issued Buy rating on July 07, 2020.
